Despite market challenges, biotech sector sees significant financing activities. Omega Funds closed a $647 million fund aimed at investing in U.S. and European life sciences startups, matching its 2021 fund size. Cooler Heads Care secured $11 million in Series A financing to expand access to chemotherapy scalp cooling devices. Avalyn Pharma raised an additional $100 million in a Series D to advance inhaled treatments for pulmonary fibrosis. Additionally, multiple biopharma and med-tech companies announced financings and expansions, reflecting cautious optimism about R&D funding futures.